Genentech, a key member of the Roche Group, has officially announced the reintroduction of Susvimo (ranibizumab injection) 100 mg/mL, a cutting-edge treatment for wet, or neovascular, age-related macular degeneration (AMD) in the United States. This comes after a voluntary recall and subsequent approval by the U.S. Food and Drug Administration (FDA) of a post-approval supplement […]
The U.S. Food and Drug Administration (FDA) has approved Xolair (omalizumab) for reducing allergic reactions, including anaphylaxis, that may occur with accidental exposure to foods in individuals aged 1 year and older with IgE-mediated food allergy. This marks a significant milestone as Xolair, produced by Genentech, a member of the Roche Group, becomes the first […]
Roche Group’s subsidiary Genentech has secured the US FDA approval for its multiple sclerosis drug, Ocrevus (ocrelizumab) for treating both relapsing and primary progressive variants of the chronic disease through intravenous infusion.
In a landmark decision, the US Food and Drug Administration (FDA) has granted approval to Genentech, a subsidiary of the Roche Group, for its multiple sclerosis (MS) drug, Ocrevus (ocrelizumab). This approval marks Ocrevus as the first and only therapy available for both relapsing and primary progressive forms of multiple sclerosis, addressing a significant unmet […]